Management of Severe Aminotransferase Elevation (>10× ULN) Without Jaundice or Hemodynamic Instability

Immediate Assessment and Monitoring

Diagnostic Workup

Treatment

Monitoring After Initiation

Common Pitfalls

Etiology‑Specific Management

Empiric Intravenous N‑Acetylcysteine for Severe Acute Hepatocellular Injury (ALT > 1200 U/L)

Guideline Recommendations

• The American Gastroenterological Association advises that N‑acetylcysteine (NAC) be used for non‑acetaminophen acute liver failure only within the context of clinical trials. 9

Mortality and Clinical Outcomes

• In patients with acute hepatic failure and ALT > 1200 U/L, intravenous NAC produced an absolute 28 % reduction in mortality and lowered the incidence of cerebral edema, independent of the timing of ingestion. (Evidence from randomized controlled trials) 9
• Post‑hoc analysis of randomized trial data showed that NAC conferred a mortality benefit specifically in patients presenting with stage 1 or stage 2 hepatic encephalopathy. (Moderate‑strength evidence) 9
• A pooled analysis of all available randomized trials indicated a marginally significant overall mortality benefit when NAC was added, with only minor toxicity reported. (Low‑to‑moderate‑strength evidence) 9

Safety Profile

• NAC is generally well‑tolerated, with the most common adverse effects being nausea and vomiting; serious reactions such as anaphylaxis occur in approximately 0.2 % of patients and hypotension in about 0.1 %. (Low‑risk safety data) 9